BIO
Dr. Andrea Anampa-Guzmán is a physician-scientist specializing in oncology drug development and clinical pharmacology. She is a Postdoctoral Fellow in Clinical Pharmacology in the Department of Oncology at Mayo Clinic, where she recently completed an NIH T32 Clinical Pharmacology Fellowship. She was also selected as an FDA–AACR Oncology Educational Fellow, training in regulatory science and FDA review methodology at the U.S. Food and Drug Administration. At Mayo Clinic, she reviews patient-level safety, PK and efficacy data across early-phase oncology trials. She also builds PK/PD, PBPK and model-informed drug development analyses to support dose selection.
Before Mayo Clinic, she spent three years in the Lymphoma Section at Roswell Park Comprehensive Cancer Center. There she contributed to multicenter U.S. cohort studies evaluating prognostic biomarkers and real-world outcomes in marginal zone, mantle cell and T-cell lymphomas. Originally from Lima, Peru, she earned her medical degree from Universidad Nacional Mayor de San Marcos. Dr. Anampa-Guzmán has authored more than 40 peer-reviewed publications in journals including Cell, Blood Advances, JCO Oncology Practice and JCO Global Oncology. She serves as Associate Editor of Cancer Investigation and reviews for 12 journals. She is a panel member on the ASCO Guideline on Management of Cancer-Related Sleep Disturbances and a member of the Survivorship Task Group of the American Cancer Society National Lung Cancer Roundtable. She has been an ASCO Featured Voice at multiple annual meetings, and she founded the first ASCO-sponsored Cancer Interest Group in South America.
Her honors include the ASCO Annual Meeting Research Award, the AACR Global Scholar-in-Training Award, the MOLA–Michael Reese Foundation Scholarship and the ASCPT Student and Trainee Community Champion award. She is ECFMG certified, holds a Graduate Certificate in Cancer Immunotherapy from SITC, and is completing the American Board of Clinical Pharmacology and RAC-Drugs certifications. Fluent in English and Spanish, she is passionate about translating pharmacology into smarter dosing decisions and clear scientific communication. She is seeking industry opportunities in clinical development, clinical pharmacology and medical affairs.
